Literature DB >> 1149806

Development of radioimmunoassay for chlorpromazine.

K Kawashima, R Dixon, S Spector.   

Abstract

Antiserum against chlorpromazine (CPZ) was produced in rabbits immunized with CPZ hapten conjugated to bovine serum albumin. The antiserum was used to develop a radioimmunoassay for CPZ. As little as 10 pg of CPZ can be detected with this radioimmunoassay. Major metabolites, CPZ sulfoxide, Nor1 -CPZ and Nor2 -CPZ are not bound significantly by the antibody unless the concentrations are very high. Although the antibody can bind 7-HO-CPZ, 8-HO-CPZ and promazine, the concentrations required to produce a 50% inhibition of 3H-CPZ-antibody binding are 5-10 times greater than CPZ. The plasma levels of CPZ and some minor metabolites in rats following administration of 10 mg/kg i.v. were determined by radioimmunoassay and showed a biphasic decay curve. Brain levels revealed that following i.v. administration CPZ traverses the blood-brain barrier rapidly and achieves peak concentration within 5 min. Plasma and brain levels can be detected for at least 24 hr.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1149806     DOI: 10.1016/0014-2999(75)90283-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF.

Authors:  G Alfredsson; B Wode-Helgodt; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1976-07-28       Impact factor: 4.530

3.  Radioimmunoassay for perphenazine in human plasma.

Authors:  K K Midha; C Mackonka; J K Cooper; J W Hubbard; P K Yeung
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

4.  Radioimmunoassay for trifluoperazine in human plasma.

Authors:  K K Midha; J W Hubbard; J K Cooper; E M Hawes; S Fournier; P Yeung
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.